{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:49:12Z","timestamp":1788461352358,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the real-world efficacy, safety, and application patterns of efgartigimod in Chinese patients with generalized myasthenia gravis (gMG), with a focus on individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center, retrospective analysis of 81 gMG patients who received at least one standard cycle of efgartigimod (10 mg\/kg weekly for 4 weeks). Disease severity was assessed using Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Composite (MGC) scores at baseline, week 2, and week 4. Retreatment and regimen modifications were individualized, which included exploration of a reduced-frequency regimen (2 infusions every 2 weeks) in selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall cohort, 65 (80.25%) and 63 (77.78%) patients achieved MG-ADL (reduction \u22652) and QMG (reduction \u22653) responses, respectively, after the first cycle. 65 (80.25%) patients received only one cycle; among them, 41 (63.07%) maintained disease control with concomitant immunosuppressive therapies without requiring additional efgartigimod. The 16 patients receiving multiple cycles (\u22652) had higher baseline disease severity (higher Myasthenia Gravis Foundation of America class, MG-ADL, and QMG scores) and showed progressive improvement with flexible retreatment. In a selected subgroup of 9 patients (based on age, robust response, and significant IgG reduction), a reduced-frequency regimen (2 infusions every 2 weeks) maintained efficacy while reducing the infusion burden. Adverse events were mostly mild, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Efgartigimod demonstrated rapid and broad efficacy in a real-world gMG cohort. An \u201cinduction-maintenance\u201d strategy, using efgartigimod for acute control and conventional immunosuppressants for long-term management, proved effective in most patients. A reduced-frequency regimen may be feasible in selected cases, highlighting the value of individualized treatment approaches in optimizing outcomes and reducing treatment burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1752846","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:38Z","timestamp":1777264118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenyu","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1407418","article-title":"Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients","volume":"15","author":"Wang","year":"2024","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08096-9","article-title":"Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience","volume":"46","author":"Antozzi","year":"2025","journal-title":"Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1558975","article-title":"The MG Composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-World experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123745","article-title":"Association of baseline acetylcholine receptor antibody levels with efgartigimod treatment efficacy for patients with myasthenia gravis","author":"Handa","year":"2025","journal-title":"J Neurol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00861-4","article-title":"Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study","author":"Gu","year":"2025","journal-title":"Neurol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28184","article-title":"Efgartigimod in refractory autoimmune myasthenia gravis","volume":"70","author":"Remijn-Nelissen","year":"2024","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2136167","article-title":"Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective","volume":"18","author":"Suzuki","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00857-0","article-title":"Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis","author":"Rini","year":"2025","journal-title":"Neurol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110457","article-title":"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients","volume":"274","author":"Zhang","year":"2025","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:39Z","timestamp":1777264119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1752846"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1752846","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1752846"}}